Method of treating diabetes

• US 5,321,009 A
• Filed: 11/14/1991
• Issued: 06/14/1994
• Est. Priority Date: 04/03/1991
• Status: Expired due to Term

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: American Home Products Corporation (Pfizer Inc.)
• Inventors: Adams, Laurel M., Baeder, William L., Caggiano, Thomas J., Sehgal, Surendra N.
• Primary Examiner(s): LEE, LESTER
• Application Number:
  US07/792,105
• Time in Patent Office: 943 Days
• Field of Search: 514/3, 514/4, 514/9, 514/291
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

This invention provides a method of prophylactically preventing the onset, preventing the development, and arresting the progression of insulin dependent diabetes mellitus in a mammal by administering an effective amount of rapamycin either alone or in combination with insulin.

Claims

1. A method for arresting the development or retarding the progression of insulin dependent diabetes mellitus in a mammal in need thereof which comprises administering an effective amount of rapamycin orally, parenterally, intranasally, intrabronchially, or rectally to said mammal.

2. The method according to claim 1 which further comprises administering the rapamycin in combination with insulin wherein the insulin is administered parenterally.

3. The method according to claim 2 wherein the amount of insulin needed to maintain normal glucose levels is less than would otherwise be needed to maintain normal glucose levels by the administration of insulin alone.

4. A composition comprising rapamycin, insulin, and a pharmaceutically acceptable carrier for the use in arresting the development or retarding the progression of insulin dependent diabetes mellitus in a mammal in need thereof.

5. The composition of claim 4 wherein the amount of insulin needed to maintain normal glucose levels is less than would otherwise be needed to maintain normal glucose levels by the administration of insulin alone.

6. A method preventing the onset of insulin dependent diabetes mellitus in an insulin dependent diabetes mellitus susceptible mammal which comprises, administering a prophylactically effective amount of rapamycin to said mammal.